Compare AstraZeneca plc (AZN) vs ProShares UltraPro QQQ ETF (TQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs ProShares UltraPro QQQ ETF — how do they compare? AstraZeneca plc trades at $158.76 (market cap $248.14B), while ProShares UltraPro QQQ ETF trades at $74.55. The key difference: AstraZeneca plc pays a 2.01% dividend while ProShares UltraPro QQQ ETF pays none, and ProShares UltraPro QQQ ETF is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.
| AZN | TQQQ | |
|---|---|---|
Market Cap | $248.14B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $209.48 | $87.22 |
52-Week Low | $147.06 | $37.89 |
Enterprise Value | $275.41B | — |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
TQQQ trades at $74.61, up 1.12% with a bullish technical signal from moving averages. The leveraged ETF benefits from strong Nasdaq-100 performance and AI-driven tech momentum. Recent institutional buying by Bay Colony Advisory Group and positive earnings from hyperscalers support current levels. However, the RSI at 74 suggests potential overbought conditions near key resistance at $75.
Outlook remains positive given tech sector strength, but volatility decay and leverage risks require careful position sizing. The ETF's structural costs compound daily, making it better suited for tactical rather than long-term holdings. Current momentum favors continued upside if tech earnings maintain strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About ProShares UltraPro QQQ ETF
TQQQ is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the Nasdaq-100 Index. It is one of the most liquid and actively traded instruments in the market, designed for sophisticated traders to amplify short-term bullish exposure to large-cap non-financial growth stocks, predominantly in the technology and communication sectors.
Read more on TQQQ →
